MAL.TO vs. VRNA

Last updated Jun 4, 2026

MAL.TO (Magellan Aerospace Corporation) and VRNA (Verona Pharma plc) are both stocks. MAL.TO operates in Aerospace & Defense (Industrials), while VRNA operates in Biotechnology (Healthcare). At a 0.06 correlation, their price movements are largely independent.

Performance

MAL.TO vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a CA$10,000 investment in Magellan Aerospace Corporation (MAL.TO) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Different Trading Currencies

MAL.TO is traded in CAD, while VRNA is traded in USD. To make them comparable, the VRNA values have been converted to CAD using the latest available exchange rates.

Returns By Period

MAL.TO

• 1D: -2.40%
• 1M: 29.52%
• YTD: 76.41%
• 6M: 100.51%
• 1Y: 88.30%
• 3Y*: 64.55%
• 5Y*: 27.47%
• 10Y*: 7.70%

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

MAL.TO vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
MAL.TO Magellan Aerospace Corporation	76.41%	85.92%	29.71%	-20.45%	3.54%	18.19%	-33.84%	-3.75%	-27.23%	3.09%
VRNA Verona Pharma plc	0.00%	123.30%	153.67%	-25.59%	316.55%	-4.87%	19.68%	-43.34%	-11.82%	-18.85%

Correlation

The correlation between MAL.TO and VRNA is 0.00, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.00
Correlation (3Y) Calculated over the trailing 3-year period	0.05
Correlation (5Y) Calculated over the trailing 5-year period	0.05
Correlation (All Time) Calculated using the full available price history since Apr 28, 2017	0.06

Fundamentals

Market Cap MAL.TO : CA$1.86B VRNA : $9.72B
EPS MAL.TO : CA$0.79 VRNA : -$0.69
PS Ratio MAL.TO : 1.74 VRNA : 57.97
PB Ratio MAL.TO : 2.22 VRNA : 34.92
Total Revenue (TTM) MAL.TO : CA$1.07B VRNA : $167.65M
Gross Profit (TTM) MAL.TO : CA$151.69M VRNA : $159.52M
EBITDA (TTM) MAL.TO : CA$115.01M VRNA : -$40.86M

Return for Risk

MAL.TO vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MAL.TO

MAL.TO Risk / Return Rank: 85
MAL.TO Sharpe Ratio Rank: 88
MAL.TO Sortino Ratio Rank: 86
MAL.TO Omega Ratio Rank: 83
MAL.TO Calmar Ratio Rank: 87
MAL.TO Martin Ratio Rank: 83

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MAL.TO vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Magellan Aerospace Corporation (MAL.TO) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MAL.TO	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	2.04	—	—
Sortino ratio: Return per unit of downside risk	2.82	—	—
Omega ratio: Gain probability vs. loss probability	1.34	—	—
Calmar ratio: Return relative to maximum drawdown	3.90	—	—
Martin ratio: Return relative to average drawdown	8.00	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	MAL.TO	VRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.04	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.80	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.22	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.03	—	—

Drawdowns

Drawdown Indicators

	MAL.TO	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-99.96%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-22.77%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-22.77%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-35.44%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-75.12%	—	—
Current Drawdown Current decline from peak	-94.18%	—	—
Average Drawdown Average peak-to-trough decline	-86.92%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	11.07%	—	—

Volatility

Volatility by Period

	MAL.TO	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.65%	—	—
Volatility (6M) Calculated over the trailing 6-month period	35.62%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	43.67%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	34.47%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	35.24%	—	—

Dividends

MAL.TO vs. VRNA - Dividend Comparison

MAL.TO's dividend yield for the trailing twelve months is around 0.61%, while VRNA has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
MAL.TO Magellan Aerospace Corporation	0.61%	0.94%	0.99%	1.27%	2.60%	4.22%	4.79%	2.88%	2.37%	1.33%	1.33%	1.39%
VRNA Verona Pharma plc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

MAL.TO vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Magellan Aerospace Corporation and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

MAL.TO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Magellan Aerospace Corporation reported a gross profit of 40.61M and revenue of 285.10M. Therefore, the gross margin over that period was 14.3%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

MAL.TO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Magellan Aerospace Corporation reported an operating income of 23.24M and revenue of 285.10M, resulting in an operating margin of 8.2%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

MAL.TO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Magellan Aerospace Corporation reported a net income of 16.48M and revenue of 285.10M, resulting in a net margin of 5.8%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both MAL.TO and VRNA in my portfolio?

MAL.TO and VRNA have a correlation of 0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.